AngioDynamics (ANGO) Stock Price Sinks As Losses Cloud Med Tech Progress

AngioDynamics just watched a long running transformation story collide with a brutal trading day. The stock sank about 21% after the Q1 2027 release, even as the medical device group posted revenue of US$80.9m and kept full year guidance intact.

For a business still reporting a net loss of US$7.1m, the headline is simple. Med Tech products are growing into almost half of sales and lifting gross margin close to 60%. However, that progress was not enough to stop investors marking the shares sharply lower on the day.

Love the shift toward higher margin Med Tech at AngioDynamics but uneasy about a business that is still loss making after a 21% one day share price drop? Take a look at our 20 high quality undiscovered gems.

Q1 2027 Earnings Summary

• Revenue (Q1 2027 vs. Q1 2026): US$80.9m vs. US$75.7m (up about 6.9%)
• Net Loss (Q1 2027 vs. Q1 2026): loss of US$7.1m vs. loss of US$10.9m (loss narrowed by about 34.9%)
• Basic EPS (Q1 2027 vs. Q1 2026): loss of US$0.17 per share vs. loss of US$0.26 per share (per share loss improved by about 36.3%)
• Gross Margin (Q1 2027): 59.4% reported, or about 57.8% excluding tariff refunds (no comparable Q1 2026 figure disclosed)

Tired of scrolling through dense earnings reports and spreadsheet rows to figure out what AngioDynamics is really doing with its money? Get a clear visual view of the group's financial health, including balance sheet strength and cash profile, in the full company report for AngioDynamics.

AngioDynamics bull case leans on Med Tech mix

For a bullish read, AngioDynamics gives you two clear hooks. Med Tech now contributes about 49% of sales, with that segment rising faster than the broader group and helping push gross margin close to 60%. Profitability is not there yet, although the loss narrowed and adjusted EBITDA more than doubled year on year. For investors banking on a higher margin, platform led story, the direction of mix, margin and earnings quality broadly lines up with that thesis, even if the share price reaction went the other way.

Share price drop keeps execution risk front and center

The bearish angle gets some backing too. The stock fell about 21% on the day, adding to double digit declines over 1, 3 and 12 months, which shows how fragile confidence is. AngioDynamics is still loss making and burned cash in Q1, even with no debt and a US$34m cash balance. Guidance calls for another year of adjusted losses, so the transformation story still relies on future delivery. For now, the market is treating execution, reimbursement and competition as live risks rather than background noise.

Compare AngioDynamics’ higher margin Med Tech push with the sharp 20.9% share price drop and ask whether analysts see a disconnect or a setup for a reset. See the consensus price target analysis for AngioDynamics to check how Wall Street is recalibrating expectations after this quarter.

Stay Ahead Of The Next Move

The 21% single day drop after AngioDynamics' Q1 2027 report is exactly the kind of volatility that calls for a clear game plan rather than a snap reaction. Register free with Simply Wall St and add AngioDynamics to your Watchlist so you can track price against fair value and watch how the Med Tech mix story evolves before deciding on your ideal entry point. When you are invested, keep your decisions grounded in data by using the Portfolio Command Center to cut through noise and surface only the key developments that matter to your holdings. Round that out with the Community to see how other investors are interpreting the same numbers so you can spot potential catalysts or risks early and stay a step ahead of the wider market.

Seeking Alternatives Beyond AngioDynamics?

Fresh ideas often emerge first when breakout stories start circulating and older themes risk drifting out of focus. Scan curated shortlists that are still under the radar for now and consider opportunities while they remain less widely followed.

• Identify cash rich businesses that may be quietly building momentum by scanning our curated list of solid balance sheet and fundamentals stocks (25 results) before the crowd starts focusing on the same resilient stories.
• Track AI-related companies that already generate profits by using the hand picked 35 profitable AI stocks that aren't just burning cash to find businesses where growth is not primarily based on burning cash.
• Follow income streams that are designed to remain steady even when sentiment shifts by reviewing the curated 8 dividend fortresses so you do not miss potential high yield candidates.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com